Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0182 |
Clopidogrel
(S)-Clopidogrel,SR-25990C,氯吡格雷 |
P2Y Receptor | GPCR/G Protein; Neuroscience |
Clopidogrel (SR-25990C) 是一种 P2Y12 受体拮抗剂,可降低血小板聚集,用于抑制冠状动脉疾病、周围血管疾病和脑血管疾病中的血凝块。 | |||
T71254 |
Clopidogrel HCl
|
||
Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. | |||
T35431 |
(±)-Clopidogrel (hydrochloride)
|
||
Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix , clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascu... | |||
T0182L |
Clopidogrel hydrogen sulfate
硫酸氢氯吡格雷,(S)-(+)-Clopidogrel hydrogen sulfate,(S)-(+)-Clopidogrel bisulfate,SR-25990C,Clopidogrel,硫酸氯吡格雷 |
P450; P2Y Receptor | GPCR/G Protein; Metabolism; Neuroscience |
Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) 是一种抗血小板药物,可防止血栓形成。它抑制 CYP2B6和 CYP2C19,IC50分别为 18.2 和 524 nM。 它是一种选择性的高亲和力 P2Y12 受体拮抗剂,可抑制纤维蛋白原与血小板的结合以及血小板的粘附和聚集。 |